On December 9, 2020, Mr. Meng Xin, CEO of BRICH held an online cooperation meeting with Mr. Enrique, Director of Foreign Investment Office, Economic Affairs Department, Economic, Innovation and Employment Bureau, Madrid City Council, Mr. David, General Manager of Madrid Science Park, Mr. Chen Wenjun, General Coordinator of Madrid China Beijing Investment Promotion Office, and Mr. Gao Haiyang, representative of China.
Mr. Enrique, Director of Foreign Investment Office, Economic Affairs Department, Economic, Innovation and Employment Bureau, Madrid City Council, introduced the current situation and needs of Spanish companies on going abroad, as well as local investment preferential policies in Spain to provide similar services for Chinese companies.
Mr. David, General Manager of Madrid Science Park, hoped to establish cooperation with Chinese companies and provide them with a full range of services. He also elaborated on the park's ranking in the EU, the number of innovative companies and investment results, and hoped to establish an innovation and R&D center with the Chinese side to promote cooperation between the two countries.
Then, Mr. Meng Xin introduced the overview of BRICH, the relevant members, the development of science and technology innovation in China and the policy of foreign investment in China.
The Spanish side expressed its recognition and affirmation of the potential of developing the Chinese market and hoped to further strengthen cooperation, hoping to promote cooperation between enterprises of both sides in R&D and innovation in high-tech fields such as biomedicine, artificial intelligence, energy saving and environmental protection. In the future cooperation, the Spanish side hopes to entrust BRICH to provide one-stop services for Spanish enterprises in high-tech fields to establish these enterprises in China.
Introduction to Spain:
Spain is a world leader in the automotive industry, new energy specialties in agriculture, aerospace, biopharmaceuticals, construction, and other fields. As one of the top ten biopharmaceutical cluster countries published by the EU, Spain has 628 pharmaceutical plants and 2140 research grants. The country has 273 biotechnology research and development institutions, the sixth highest industrial application rate in Europe, and strong research strength in basic biotechnology research, human health, veterinary medicine, and medical restorative skin care. Grifols, the world's first company with plasma collection capabilities, and Zeltia, which produced the world's first marine antitumor drug, are both from Spain.
The city of Madrid is the capital of Spain and is the political, cultural, economic and financial center of the country. Madrid is also the integrated economic center of Spain's Central Economic Zone, the center of transportation, logistics, research and development, consumer and high-tech industries. The Madrid Science Park, set up by five science and technology institutions, is located 7 km from the center of Madrid, near several universities and national research institutions, and is currently home to 83 companies, having incubated more than 300 companies, with an incubation success rate of more than 80%.